Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $89,863.72 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 3,236 shares of the company’s stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $27.77, for a total transaction of $89,863.72. Following the completion of the transaction, the insider now owns 170,285 shares in the company, valued at approximately $4,728,814.45. This represents a 1.86 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, February 18th, Soleil Boughton sold 4,152 shares of Hims & Hers Health stock. The shares were sold at an average price of $60.69, for a total transaction of $251,984.88.
• On Monday, February 3rd, Soleil Boughton sold 4,153 shares of Hims & Hers Health stock. The stock was sold at an average price of $35.30, for a total transaction of $146,600.90.
• On Tuesday, January 21st, Soleil Boughton sold 54,153 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.90, for a total transaction of $1,619,174.70.
• On Monday, January 6th, Soleil Boughton sold 268,932 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.75, for a total value of $7,462,863.00.

Hims & Hers Health Stock Performance

Shares of HIMS traded up $1.49 during mid-day trading on Tuesday, hitting $31.04. 45,978,327 shares of the company were exchanged, compared to its average volume of 14,436,744. Hims & Hers Health, Inc. has a 1-year low of $11.20 and a 1-year high of $72.98. The company has a 50 day moving average of $39.92 and a 200-day moving average of $29.67. The stock has a market cap of $6.90 billion, a price-to-earnings ratio of 70.54 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on HIMS. Piper Sandler boosted their price target on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 25th. Morgan Stanley cut Hims & Hers Health from an “overweight” rating to an “equal weight” rating and raised their price target for the company from $42.00 to $60.00 in a report on Tuesday, February 18th. Leerink Partners increased their target price on Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research report on Tuesday, February 25th. Truist Financial boosted their price target on shares of Hims & Hers Health from $24.00 to $39.00 and gave the stock a “hold” rating in a research report on Wednesday, February 26th. Finally, BTIG Research assumed coverage on Hims & Hers Health in a report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $37.31.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in Hims & Hers Health by 11.1% in the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock worth $489,817,000 after acquiring an additional 2,020,722 shares during the last quarter. Farallon Capital Management LLC increased its holdings in shares of Hims & Hers Health by 64,338.5% in the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock valued at $202,556,000 after acquiring an additional 8,364,000 shares during the period. Renaissance Technologies LLC grew its holdings in shares of Hims & Hers Health by 29.0% during the fourth quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock worth $168,079,000 after buying an additional 1,562,302 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Hims & Hers Health by 192.0% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock valued at $152,436,000 after purchasing an additional 4,145,305 shares during the period. Finally, State Street Corp lifted its stake in shares of Hims & Hers Health by 4.7% in the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company’s stock worth $85,221,000 after acquiring an additional 206,078 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.